UNRESECTABLE COLON ADENOCARCINOMA
Clinical trials for UNRESECTABLE COLON ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE COLON ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for UNRESECTABLE COLON ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for hard-to-treat colorectal cancer: drug duo aims to shrink tumors
Disease control OngoingThis study tests a combination of two drugs, SX-682 and nivolumab, in people with a specific type of advanced colorectal cancer (RAS-mutated, MSS) that has spread or can't be removed. The goal is to see if the combo can shrink tumors or slow the cancer's growth. About 51 adults w…
Matched conditions: UNRESECTABLE COLON ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 08:28 UTC
-
New drug cocktail aims to shrink Hard-to-Treat colorectal tumors
Disease control OngoingThis study tests whether adding two targeted drugs (LY3214996 and abemaciclib) to the standard drug cetuximab can shrink tumors in people with advanced colorectal cancer that no longer responds to standard treatment. About 46 adults with metastatic or inoperable colorectal cancer…
Matched conditions: UNRESECTABLE COLON ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
Triple-Drug cocktail shows promise for Tough-to-Treat colorectal cancer
Disease control OngoingThis study tests a combination of two targeted drugs (encorafenib and cetuximab) plus an immunotherapy drug (nivolumab) in people with advanced colorectal cancer that has a specific BRAF gene change and has not responded to standard treatments. The goal is to see if this triple t…
Matched conditions: UNRESECTABLE COLON ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
Could adding an immunotherapy drug shrink tough colorectal tumors?
Disease control OngoingThis study is for people with a specific type of advanced colorectal cancer that has a BRAF gene mutation and is stable (not the MSI-high type). It compares the usual two-drug treatment (encorafenib and cetuximab) against the same two drugs plus an immunotherapy drug called nivol…
Matched conditions: UNRESECTABLE COLON ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:50 UTC